Managing Bone Health in Breast Cancer

Kearns, Ann E.

doi:10.1016/j.eprac.2022.12.003

Cited by 3 publications

(1 citation statement)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, any patient initiating or receiving AI therapy with a T-score <-2.0 should receive antiresorptive therapy regardless of the presence of other risk factors. Based on current evidence, subcutaneous denosumab and bisphosphonates are the preferred agents for the prevention and treatment of AIBL [7], [8].…”

Section: Introductionmentioning

confidence: 99%

Bone loss and osteosarcopenia induced by aromatase inhibitor treatment in elderly patients with breast cancer: the role of intervention with inhibitors of RANK/RANKL system

casabella,

Paladin,

ottaviani

et al. 2024

Preprint

View full text Add to dashboard Cite

This study explores the efficacy of desonumab in mitigating aromatase inhibitor-induced bone loss (AIBL) and osteosarcopenia in elderly women with breast cancer. The study involved 60 patients (female sex > or equal 65) with non-metastatic breast cancr and undegoing adiuvant endocreine therapy (Letrozole and Tamoxifen). Patients were divided as follows: 30 patients undergoing denosumab therapy (60 mg via subcutaneous injection every 6 months) and 30 patients undergoing bisphosphonate therapy (oral alendronate 70 mg/week). For each patient of the desonumab group bone status and muscoloskeletal composition was assessed by bone densitometry together with comprehensive geriatric assessment (CGA) and body composition at baseline and after one year of treatment. A significant improvement for trabecular bone score (TBS) at hte lumbar spine, relative skeletal muscle index (RSMI) and whole-body composition (arm, legs and trunk) were observed in the desonumab group compared with the bisphopshonate group. These findings underscore the role of desonumab as an effective strategy in managing AIBL and osteosarcopenia in elderly women with breast cancer and undergoing adjuvant endocrine therapy, which is crucial for improving quality of life, preventing functional decline, and optimizing treatment outcomes

show abstract

Section: Introductionmentioning

confidence: 99%